title: Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.
abstract: The overall survival of patients with acute myeloid leukemia (AML) has not been improved significantly over the last decade. Molecularly targeted agents hold promise to change the therapeutic landscape in AML. The nuclear factor kappa B (NF-κB) controls a plethora of biological process through switching on and off its long list of target genes. In AML, constitutive NF-κB has been detected in 40% of cases and its aberrant activity enable leukemia cells to evade apoptosis and stimulate proliferation. These facts suggest that NF-κB signaling pathway plays a fundamental role in the development of AML and it represents an attractive target for the intervention of AML. This review summarizes our current knowledge of NF-κB signaling transduction including canonical and non-canonical NF-κB pathways. Then we specifically highlight what factors contribute to the aberrant activation of NF-κB activity in AML, followed by an overview of 8 important clinical trials of the first FDA approved proteasome inhibitor, Bortezomib (Velcade), which is a NF-κB inhibitor too, in combination with other therapeutic agents in patients with AML. Finally, this review discusses the future directions of NF-κB inhibitor in treatment of AML, especially in targeting leukemia stem cells (LSCs).
authors.affiliation: Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, Singapore, Republic of Singapore.
authors.forename: Jianbiao
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, Singapore, Republic of Singapore.
authors.forename: Ying Qing
authors.initials: YQ
authors.lastname: Ching
authors.affiliation: Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, Singapore, Republic of Singapore.|Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.|Department of Hematology-Oncology, National University Cancer Institute of Singapore (NCIS), The National University Health System (NUHS), Singapore, Republic of Singapore.
authors.forename: Wee-Joo
authors.initials: WJ
authors.lastname: Chng
mesh_terms: D000818:Animals; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000378:metabolism*
chemical_list: D016328:NF-kappa B
keywords: Bortezomib; NF-κB; Velcade; acute myeloid leukemia; leukemia
references.citation: Crit Rev Oncog. 2011;16(1-2):93-102
references.pmid: 22150310
references.citation: Biochem Pharmacol. 2006 Oct 30;72(9):1069-80
references.pmid: 16854381
references.citation: Front Biosci (Landmark Ed). 2012 Jan 01;17(3):1120-39
references.pmid: 22201794
references.citation: Leukemia. 2001 Apr;15(4):688-9
references.pmid: 11368383
references.citation: Nat Rev Cancer. 2010 Aug;10(8):561-74
references.pmid: 20651737
references.citation: Apoptosis. 2008 Sep;13(9):1148-61
references.pmid: 18670883
references.citation: Thyroid. 2013 Feb;23(2):209-18
references.pmid: 23273524
references.citation: Cancer Lett. 2012 Sep 28;322(2):119-26
references.pmid: 22433713
references.citation: Leukemia. 2013 Sep;27(9):1793-802
references.pmid: 23817177
references.citation: Clin Cancer Res. 2004 May 15;10(10):3371-6
references.pmid: 15161691
references.citation: Oncogene. 2006 Oct 30;25(51):6706-16
references.pmid: 17072323
references.citation: Blood. 2012 Jun 21;119(25):6025-31
references.pmid: 22566605
references.citation: Ann Oncol. 2004 Jun;15(6):885-90
references.pmid: 15151944
references.citation: Nitric Oxide. 2010 Sep 15;23(2):75-93
references.pmid: 20438856
references.citation: Blood. 2007 Dec 15;110(13):4427-35
references.pmid: 17804695
references.citation: Genes Dev. 2012 Feb 1;26(3):203-34
references.pmid: 22302935
references.citation: Leuk Res. 2005 Aug;29(8):893-9
references.pmid: 15978940
references.citation: Blood. 2012 Oct 25;120(17):3397-406
references.pmid: 22898602
references.citation: Biomed J. 2014 Jan-Feb;37(1):3-9
references.pmid: 24667671
references.citation: J Clin Invest. 2014 Feb;124(2):528-42
references.pmid: 24382349
references.citation: J Clin Oncol. 2013 Mar 1;31(7):923-9
references.pmid: 23129738
references.citation: Expert Opin Ther Targets. 2013 Sep;17(9):1091-108
references.pmid: 23822887
references.citation: Acta Haematol. 2001;106(3):95-9
references.pmid: 11713373
references.citation: J Biol Chem. 1998 Jan 2;273(1):592-9
references.pmid: 9417120
references.citation: World J Stem Cells. 2014 Sep 26;6(4):473-84
references.pmid: 25258669
references.citation: Int J Cancer. 2013 Mar 15;132(6):1260-71
references.pmid: 23180629
references.citation: Oncogene. 2006 Oct 30;25(51):6680-4
references.pmid: 17072321
references.citation: Blood. 2011 Dec 15;118(25):6626-37
references.pmid: 22021368
references.citation: Mol Cancer Ther. 2003 Aug;2(8):815-23
references.pmid: 12939472
references.citation: Eur J Biochem. 1996 Aug 1;239(3):566-71
references.pmid: 8774698
references.citation: Immunol Rev. 2012 Mar;246(1):183-92
references.pmid: 22435555
references.citation: Blood Cells Mol Dis. 2010 Apr 15;44(4):275-86
references.pmid: 20144877
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1140-6
references.pmid: 21233404
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1446-54
references.pmid: 18316568
references.citation: Cell Rep. 2014 Sep 11;8(5):1328-38
references.pmid: 25199827
references.citation: Cell Res. 2011 Jan;21(1):71-85
references.pmid: 21173796
references.citation: Blood. 2002 Aug 1;100(3):879-87
references.pmid: 12130498
references.citation: Drug Discov Today. 2013 Sep;18(17-18):894-905
references.pmid: 23688583
references.citation: Leuk Lymphoma. 2014 Jun;55(6):1304-8
references.pmid: 23952243
references.citation: J Exp Med. 2014 Jun 2;211(6):1093-108
references.pmid: 24842373
references.citation: Blood Cells Mol Dis. 2014 Jan;52(1):2-11
references.pmid: 23890415
references.citation: Nat Rev Cancer. 2012 Jan 19;12(2):121-32
references.pmid: 22257950
references.citation: Cancer Lett. 2013 Sep 10;338(1):10-4
references.pmid: 22820159
references.citation: Oncotarget. 2010 May;1(1):59-68
references.pmid: 20890394
references.citation: Cancer Cell. 2006 Sep;10(3):215-26
references.pmid: 16959613
references.citation: Nat Med. 1997 Jul;3(7):730-7
references.pmid: 9212098
references.citation: Leuk Res. 2013 Nov;37(11):1502-8
references.pmid: 24075534
references.citation: J Leukoc Biol. 2013 Nov;94(5):941-51
references.pmid: 23922380
references.citation: Oncotarget. 2010 Sep;1(5):359-366
references.pmid: 21307400
references.citation: Mol Cancer Res. 2008 Jan;6(1):78-88
references.pmid: 18234964
references.citation: Leukemia. 2009 Feb;23(2):365-74
references.pmid: 18987666
references.citation: Clin Sci (Lond). 2009 Mar;116(6):451-65
references.pmid: 19200055
references.citation: J Exp Med. 2014 Jan 13;211(1):1-4
references.pmid: 24395889
references.citation: Cell Mol Life Sci. 2014 Jun;71(11):2083-102
references.pmid: 24419302
references.citation: Blood. 2008 Dec 15;112(13):4793-807
references.pmid: 19064739
references.citation: J Hematol Oncol. 2009 Jul 30;2:33
references.pmid: 19642998
references.citation: Genes Dev. 1995 Nov 15;9(22):2723-35
references.pmid: 7590248
references.citation: Leukemia. 2005 Mar;19(3):329-34
references.pmid: 15674366
references.citation: Int J Cancer. 2009 Dec 15;125(12):2863-70
references.pmid: 19609947
references.citation: Leukemia. 2009 Jan;23(1):25-42
references.pmid: 18800146
references.citation: Carcinogenesis. 2009 Jul;30(7):1073-81
references.pmid: 19468060
references.citation: Expert Opin Ther Targets. 2013 May;17(5):507-31
references.pmid: 23360111
references.citation: Nat Rev Mol Cell Biol. 2013 Apr;14(4):197-210
references.pmid: 23847781
references.citation: Crit Rev Oncog. 2009;15(1-2):1-41
references.pmid: 20136626
references.citation: J Immunol. 2009 May 1;182(9):5757-62
references.pmid: 19380823
references.citation: Oncogene. 2006 Oct 30;25(51):6887-99
references.pmid: 17072334
references.citation: Nat Cell Biol. 2012 Dec;14(12):1270-81
references.pmid: 23159929
references.citation: Neoplasma. 2006;53(6):518-23
references.pmid: 17167722
references.citation: Acta Oncol. 2005;44(5):440-8
references.pmid: 16118077
references.citation: Appl Clin Genet. 2014 Sep 10;7:159-67
references.pmid: 25258552
references.citation: Hematology Am Soc Hematol Educ Program. 2004;:98-117
references.pmid: 15561679
references.citation: Leukemia. 2004 Jan;18(1):103-12
references.pmid: 14574326
references.citation: Mol Cancer Res. 2011 Oct;9(10):1395-405
references.pmid: 21813505
references.citation: Virchows Arch. 2005 May;446(5):475-82
references.pmid: 15856292
references.citation: Blood. 2011 Apr 14;117(15):4085-94
references.pmid: 21346255
references.citation: Nat Rev Drug Discov. 2008 Dec;7(12):1031-40
references.pmid: 19043452
references.citation: Blood. 2002 Oct 15;100(8):2717-23
references.pmid: 12351377
references.citation: Leuk Lymphoma. 2013 Sep;54(9):1996-2002
references.pmid: 23256542
references.citation: Curr Mol Pharmacol. 2010 Nov;3(3):98-122
references.pmid: 20594187
references.citation: Oncotarget. 2011 Sep;2(9):658-68
references.pmid: 21911919
references.citation: Oncotarget. 2010 Jun;1(2):89-103
references.pmid: 20671809
references.citation: Immunol Rev. 2012 Mar;246(1):5-13
references.pmid: 22435544
references.citation: Apoptosis. 2009 Apr;14(4):348-63
references.pmid: 19212815
references.citation: Nature. 1998 Jan 22;391(6665):410-3
references.pmid: 9450761
references.citation: Curr Drug Targets. 2010 Jan;11(1):95-110
references.pmid: 20017722
references.citation: EMBO Rep. 2014 Jan;15(1):46-61
references.pmid: 24375677
references.citation: World J Urol. 2012 Jun;30(3):303-10
references.pmid: 22085980
references.citation: Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):569-74
references.pmid: 9012825
references.citation: J Clin Oncol. 2005 Jul 20;23(21):4776-89
references.pmid: 16034054
references.citation: Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S1-10
references.pmid: 22443181
references.citation: Trends Pharmacol Sci. 2009 Jun;30(6):313-21
references.pmid: 19446347
references.citation: Oncogene. 2009 Jun 4;28(22):2205-18
references.pmid: 19398952
references.citation: Biochem Soc Symp. 2006;(73):165-80
references.pmid: 16626297
references.citation: Curr Pharm Des. 2013;19(18):3263-75
references.pmid: 23151140
references.citation: Nat Genet. 2001 Mar;27(3):263-70
references.pmid: 11242107
references.citation: Leuk Res. 2013 Sep;37(9):1016-20
references.pmid: 23773898
references.citation: Curr Opin Genet Dev. 2008 Feb;18(1):19-26
references.pmid: 18440219
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):340-4
references.pmid: 16428470
references.citation: Cancer Control. 2005 Apr;12(2):91-104
references.pmid: 15855892
references.citation: Semin Immunol. 2014 Jun;26(3):253-66
references.pmid: 24958609
references.citation: Cancer Res. 2010 Apr 1;70(7):2973-83
references.pmid: 20332229
references.citation: Oncologist. 2007 Jun;12(6):664-89
references.pmid: 17602058
references.citation: Int J Hematol. 2013 Jun;97(6):726-34
references.pmid: 23613270
references.citation: Blood. 2009 Apr 23;113(17):4052-62
references.pmid: 19144991
references.citation: Front Immunol. 2013 Nov 15;4:376
references.pmid: 24298274
references.citation: Blood. 2000 Sep 1;96(5):1655-69
references.pmid: 10961860
references.citation: Annu Rev Biophys. 2013;42:443-68
references.pmid: 23495970
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):360-369
references.pmid: 22096027
references.citation: Cell Stem Cell. 2014 Mar 6;14(3):275-91
references.pmid: 24607403
references.citation: Blood. 2008 Apr 1;111(7):3793-801
references.pmid: 18202225
references.citation: Bioorg Med Chem Lett. 2009 Aug 1;19(15):4346-9
references.pmid: 19505822
references.citation: Mol Cancer Res. 2005 Oct;3(10):585-96
references.pmid: 16254192
references.citation: Immunol Rev. 2011 Nov;244(1):44-54
references.pmid: 22017430
references.citation: Endocr Relat Cancer. 2010 Jan 29;17(1):F19-36
references.pmid: 19779035
references.citation: Mol Cell Biol. 1999 Jul;19(7):4547-51
references.pmid: 10373503
references.citation: Chromosoma. 2014 Dec;123(6):545-61
references.pmid: 25112726
references.citation: Oncogene. 2009 Feb 26;28(8):1099-109
references.pmid: 19079347
references.citation: Oncogene. 1997 Dec 11;15(24):2965-74
references.pmid: 9416840
references.citation: Annu Rev Immunol. 1996;14:649-83
references.pmid: 8717528
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2739-47
references.pmid: 20439648
references.citation: Cancer Invest. 2000;18(8):768-80
references.pmid: 11107447
references.citation: Mol Cancer. 2013 Aug 02;12:86
references.pmid: 23915189
references.citation: Blood. 2001 Oct 15;98(8):2301-7
references.pmid: 11588023
references.citation: Curr Cancer Drug Targets. 2014;14(4):337-47
references.pmid: 24655000
references.citation: PLoS One. 2014 Sep 22;9(9):e107587
references.pmid: 25244440
references.citation: Cell Res. 2011 Jan;21(1):86-102
references.pmid: 21102550